Related Experiment Video

Updated: Jul 8, 2025

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

14.9K

Targeting CRAF kinase in anti-cancer therapy: progress and opportunities

Penglei Wang1,2,3, Kyle Laster3, Xuechao Jia1,2,3

  • 1Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, 450000, China.

Molecular Cancer
|December 19, 2023
PubMed

Insights

Targeting CRAF (RAF kinase) is crucial for cancers driven by RAS/RAF oncogenes. This review explores CRAF

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Signaling Pathways

Background:

  • The RAS/mitogen-activated protein kinase (MAPK) pathway is frequently dysregulated in cancers due to RAS or RAF oncogenes.
  • CRAF, a RAF kinase family member, is integral to the RAS-MAPK pathway and cancer progression.
  • CRAF's roles in physiological regulation and resistance to BRAF inhibitors, via MAPK-dependent and -independent mechanisms, are increasingly recognized.

Purpose of the Study:

  • To investigate CRAF alterations across various cancers and its distinct roles in oncogene-driven malignancies.
  • To summarize CRAF-interacting proteins and its regulation in cancer hallmarks.
  • To discuss advancements in pan-RAF inhibitors and combination therapies for improved efficacy and reduced toxicity in RAF/RAS-mutant tumors.

Main Methods:

  • Literature review of CRAF alterations, functions, and interactions in cancer.
  • Analysis of current therapeutic strategies targeting CRAF and RAF inhibitors.
  • Exploration of resistance mechanisms and potential synergistic targets.

Main Results:

  • CRAF plays a multifaceted role in cancer, with its kinase activity and independent functions contributing to tumorigenesis and drug resistance.
  • Solely targeting CRAF kinase activity shows controversial effectiveness; its kinase-independent functions may be critical in KRAS-mutant lung cancers.
  • Recent advances include pan-RAF inhibitors and combination therapies showing promise for RAF/RAS-mutant cancers.

Conclusions:

  • A comprehensive understanding of CRAF's diverse roles is essential for developing effective cancer treatments.
  • Identifying synergistic targets and elucidating resistance pathways are key to advancing combination strategies.
  • Future strategies should focus on robust and safer combination therapies for RAF/RAS-driven tumors.
Keywords:
CRAFCombination therapyMAPK signaling pathwayPan-RAF inhibitorsRAF heterodimers

More Related Videos

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.3K
Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay12:26

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay

Published on: May 3, 2018

18.7K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.6K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K